ProCE Banner Activity

DESTINY-Lung02: Final Analysis of Trastuzumab Deruxtecan in Previously Treated HER2-Mutated Metastatic NSCLC

Conference Coverage

In this final analysis of the phase II DESTINY-Lung02 trial, T-DXd continued to show durable responses in patients with previously treated HER2-mutated metastatic NSCLC, with ORRs of 50% and 56% with T-DXd 5.4 and 6.4 mg/kg, respectively.

Released: June 06, 2024

Expiration: June 05, 2025


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.